Herr H, Vertosick EA, Dalbagni G, et al. - The results showed that in patients with high-risk non–muscle-invasive bladder cancer, a high response rate justifies 2 BCG induction cycles in current practice.

• Researchers enrolled patients with primary or recurrent NMIBC (high-grade Ta, T1 tumors, with or without CIS) to receive 2-induction courses (12 intravesical instillations) of BCG between 2015 and 2018.

• A total of 81 patients were included in this study.

• The results showed that five withdrew before starting BCG, leaving 76 evaluable patients.

• There were 63 patients (83%) who completed the 12 installations on schedule.

• Of these, at 6 months, 62 patients (91%) had a complete response.

• They did not find tumor progression in any patient.

• There was a serious adverse event in 1 patient (1%). As per the findings, 85% was the recurrence-free survival at 2 years after the complete response (95% CI 77%, 95%).